1 0

    FDA ANNUAL REPORT FOR ANDEXXA (NDA BY ASTRAZENECA) RECEIVED 06/30/22

    FDA ANNUAL REPORT FOR ANDEXXA (NDA BY ASTRAZENECA) RECEIVED 06/30/22

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request: The annual report submitted by AstraZeneca AB to the FDA for the product: andexxa, Coagulation Factor Xa (Recombinant), Inactivated-zhzo. The annual report is stated to be received by the FDA on 6/30/22.
    Tags: Pharma, BLA, 2022
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details